ABCL
AbCellera Accelerates Towards a Milestone as ABCL635 Showcases Robust Efficacy
AbCellera, a biotechnology company dedicated to accelerating the discovery of novel therapeutics, has made significant strides in its second quarter of 2026. As revealed during their recent conference call, AbCellera's President and CEO, Dr. Carl Hansen, highlighted the top-line results for ABCL635 in the treatment of moderate to